CoChat

Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis

Open access

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

The small heterodimer partner (SHP) is an orphan nuclear receptor that lacks the DNA binding domain while conserves a putative ligand-binding site, thought that endogenous ligands for this receptor are unknown. Previous studies have determined that SHP activation protects against development of liver fibrosis a process driven by trans-differentiation and activation of hepatic stellate cells (HSCs), a miofibroblast like cell type, involved in extracellular matrix (ECM) deposition. To dissect signals involved in this activity we generated SHP-overexpressing human and rat HSCs. Forced expression of SHP in HSC-T6 altered the expression of 574 genes. By pathway and functional enrichment analyses we detected a cluster of 46 differentially expressed genes involved in HSCs trans-differentiation. Using a isoxazole scaffold we designed and synthesized a series of SHP agonists. The most potent member of this group, ISO-COOH (EC 50: 9 μM), attenuated HSCs trans-differentiation and ECM deposition in vitro, while in mice rendered cirrhotic by carbon tetrachloride (CCl 4) or α-naphthyl-isothiocyanate (ANIT), protected against development of liver fibrosis as measured by morphometric analysis and expression of α-SMA and α1-collagen mRNAs. In aggregate, present results identify SHP as a counter-regulatory signal for HSCs transactivation and describe a novel class of SHP agonists endowed with anti-fibrotic activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep41055

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 SHP overexpression or CDCA modulates common target genes in HSC. (A) Venn diagram of DEGs genes in HSC-T6 stimulated with CDCA and HSC-T6 overexpressing SHP. (B) Pathway analysis showing the top enriched canonical pathways. The enrichment of canonical pathways in the differentially expressed genes has been identified by KOBAS 2.0 software.
Figure 1 SHP overexpression or CDCA modulates common target genes in HSC. (A) Venn diagram of DEGs genes in HSC-T6 stimulated with CDCA and HSC-T6 overexpressing SHP. (B) Pathway analysis showing the top enriched canonical pathways. The enrichment of canonical pathways in the differentially expressed genes has been identified by KOBAS 2.0 software.CC BY · PubMed Central
Figure 2 Microarray validation of gene array of SHP regulated genes using the RT2 Profiler™ PCR Array. (A,B) Scatter plot and clustergram of microarray data showing DEGs that are regulated by SHP (positively in red, negatively in green) in HSC-T6 stimulated with CDCA (A) or HSC-T6 overexpressing SHP (B). (C) Effect of CDCA treatment (white bars) and SHP over-expression (black bars) on the relative mRNA expression of CXCL12, TGFBR2, DAG1 GR, NCoR1 and Rb1.
Figure 2 Microarray validation of gene array of SHP regulated genes using the RT2 Profiler™ PCR Array. (A,B) Scatter plot and clustergram of microarray data showing DEGs that are regulated by SHP (positively in red, negatively in green) in HSC-T6 stimulated with CDCA (A) or HSC-T6 overexpressing SHP (B). (C) Effect of CDCA treatment (white bars) and SHP over-expression (black bars) on the relative mRNA expression of CXCL12, TGFBR2, DAG1 GR, NCoR1 and Rb1.CC BY · PubMed Central
Figure 3 Identification and characterization of SHP agonists. (A) Molecular structures of compounds 1–7. (B,C) Transactivation assay on SHP ligand binding domain. HepG2 cells were transiently transfected with the fusion protein SHP/GAL4 and with the reporter vector pGL4.35. 24 hours post-transfection Cells were stimulated with 10 μM (B) or 50 μM (C) compounds 1–7 and with 10 or 50 μM all trans retinoic acid (ATRA), used as a positive control. Results are expressed as the mean ± standard error (*p < 0.05 vs not treated cells (NT). (D) Concentration−response curves for compounds 1 and 2 (ISO-COOH). HepG2 cells transiently transfected with the fusion protein SHP/GAL4 and with the reporter vector pGL4.35 were stimulated with increasing concentrations of compounds 1 and 2 (1, 10 and 50 μM). ATRA (1, 10 and 50 μM) was used as a positive control to evaluate the SHP ligand binding domain activity.
Figure 3 Identification and characterization of SHP agonists. (A) Molecular structures of compounds 1–7. (B,C) Transactivation assay on SHP ligand binding domain. HepG2 cells were transiently transfected with the fusion protein SHP/GAL4 and with the reporter vector pGL4.35. 24 hours post-transfection Cells were stimulated with 10 μM (B) or 50 μM (C) compounds 1–7 and with 10 or 50 μM all trans retinoic acid (ATRA), used as a positive control. Results are expressed as the mean ± standard error (*p < 0.05 vs not treated cells (NT). (D) Concentration−response curves for compounds 1 and 2 (ISO-COOH). HepG2 cells transiently transfected with the fusion protein SHP/GAL4 and with the reporter vector pGL4.35 were stimulated with increasing concentrations of compounds 1 and 2 (1, 10 and 50 μM). ATRA (1, 10 and 50 μM) was used as a positive control to evaluate the SHP ligand binding domain activity.CC BY · PubMed Central
Figure 4 SHP agonism reverses the pro-fibrotic phenotype induces by TGFβ1 in rat HSC. Rat HSC-T6 and HSC-T6 overexpressing SHP were used. (A,B). Serum starved HSC-T6 were stimulated 18 hours with 10 ng/ml TGFβ1 alone or in combination with 50 μM ISO-COOH. At the end of stimulation the relative mRNA expression of αSMA and COL1α1 was assayed by Real-Time PCR. (C,D) Serum starved HSC-T6 overexpressing SHP were stimulated 18 hours with 10 ng/ml TGFβ1 alone or in combination with 50 μM ISO-COOH. At the end of stimulation the relative mRNA expression of αSMA and COL1α1 was assayed by Real-Time PCR. Values are normalized relative to GAPDH mRNA and are expressed relative to those of not treated cells (NT), which are arbitrarily set to 1. *p < 0.05 vs NT; #p < 0.05 vs TGFβ1.
Figure 4 SHP agonism reverses the pro-fibrotic phenotype induces by TGFβ1 in rat HSC. Rat HSC-T6 and HSC-T6 overexpressing SHP were used. (A,B). Serum starved HSC-T6 were stimulated 18 hours with 10 ng/ml TGFβ1 alone or in combination with 50 μM ISO-COOH. At the end of stimulation the relative mRNA expression of αSMA and COL1α1 was assayed by Real-Time PCR. (C,D) Serum starved HSC-T6 overexpressing SHP were stimulated 18 hours with 10 ng/ml TGFβ1 alone or in combination with 50 μM ISO-COOH. At the end of stimulation the relative mRNA expression of αSMA and COL1α1 was assayed by Real-Time PCR. Values are normalized relative to GAPDH mRNA and are expressed relative to those of not treated cells (NT), which are arbitrarily set to 1. *p < 0.05 vs NT; #p < 0.05 vs TGFβ1.CC BY · PubMed Central
Figure 5 SHP agonism reverses the pro-fibrotic phenotype induced by TGFβ1 in human HSC. HSC-LX2 and HSC-LX2 overexpressing SHP were used. (A,B). Serum starved HSC-LX2 were activated with 10 ng/ml TGFβ1 and stimulated 18 hours with 50 μM CDCA and ISO-COOH 50 μM or with a combination of both agents. At the end of stimulation the relative mRNA expression of αSMA and COL1α1 was assayed by Real-Time PCR. (C,D) Serum starved HSC-LX2 overexpressing SHP were exposed to 10 ng/ml TGFβ1 for 18 h alone or in combination with 50 μM CDCA and 50 μM ISO-COOH or with a combination of both agents. At the end of the study cells were harvested and relative mRNA expression of αSMA and COL1α1 assayed by Real-Time PCR. Values were normalized relative to GAPDH mRNA and not treated cells (NT) were arbitrarily set to 1. *p < 0.05 vs NT; #p < 0.05 vs TGFβ1.
Figure 5 SHP agonism reverses the pro-fibrotic phenotype induced by TGFβ1 in human HSC. HSC-LX2 and HSC-LX2 overexpressing SHP were used. (A,B). Serum starved HSC-LX2 were activated with 10 ng/ml TGFβ1 and stimulated 18 hours with 50 μM CDCA and ISO-COOH 50 μM or with a combination of both agents. At the end of stimulation the relative mRNA expression of αSMA and COL1α1 was assayed by Real-Time PCR. (C,D) Serum starved HSC-LX2 overexpressing SHP were exposed to 10 ng/ml TGFβ1 for 18 h alone or in combination with 50 μM CDCA and 50 μM ISO-COOH or with a combination of both agents. At the end of the study cells were harvested and relative mRNA expression of αSMA and COL1α1 assayed by Real-Time PCR. Values were normalized relative to GAPDH mRNA and not treated cells (NT) were arbitrarily set to 1. *p < 0.05 vs NT; #p < 0.05 vs TGFβ1.CC BY · PubMed Central
Figure 6 SHP activation protects against liver fibrosis in the CCL4 model. (A) Effect of compound 2 on AST, Albumin and Bilirubin in mice rendered cirrhotic by administration of CCl4. Mice were administered CCl4 for 3 weeks and after the first week of treatment randomized to receive CDCA, 5 mg/kg/day, alone or in combination with ISO-COOH, 30 mg/kg/day. (B) Hematoxylin and eosin (H&E) staining. (C) Syrius red staining. (D) Image J quantification of Syrius red staining. (E) Effect of CDCA (5 mg/kg) or ISOCOOH (30 mg/kg) on fibrotic genes in CCl4-treated mice. The relative hepatic mRNA expression of αSMA, COL1α1, TGFβ1, IL1β, FXR, SHP and BSEP was assayed by Real-Time PCR. Results are the mean ± SE of 4–6 mice per group. *p < 0.05 versus naïve mice. #p < 0.05 versus CCl4 alone.
Figure 6 SHP activation protects against liver fibrosis in the CCL4 model. (A) Effect of compound 2 on AST, Albumin and Bilirubin in mice rendered cirrhotic by administration of CCl4. Mice were administered CCl4 for 3 weeks and after the first week of treatment randomized to receive CDCA, 5 mg/kg/day, alone or in combination with ISO-COOH, 30 mg/kg/day. (B) Hematoxylin and eosin (H&E) staining. (C) Syrius red staining. (D) Image J quantification of Syrius red staining. (E) Effect of CDCA (5 mg/kg) or ISOCOOH (30 mg/kg) on fibrotic genes in CCl4-treated mice. The relative hepatic mRNA expression of αSMA, COL1α1, TGFβ1, IL1β, FXR, SHP and BSEP was assayed by Real-Time PCR. Results are the mean ± SE of 4–6 mice per group. *p < 0.05 versus naïve mice. #p < 0.05 versus CCl4 alone.CC BY · PubMed Central
Figure 7 SHP agonism protects against liver fibrosis development in a mice model of cholestasis. (A) Effect of ISO-COOH on AST and Alkaline phosphatase in mice administered α-naphthyl-isothiocyanate (ANIT), 10 mg/kg per os for 4 weeks. Mice were randomized after 2 weeks to receive CDCA (5 mg/kg) alone or in combination with ISO-COOH (30 mg/Kg), or ISO-COOH alone (30 mg/Kg), for two additional weeks. Data shown are: (B) Hematoxylin and eosin (H&E) staining. (C) Syrius red staining. (D) Image J quantification of Syrius red staining. Results are the mean ± SE of 6–9 mice per group. *p < 0.05, **p < 0.005, ***p < 0.0005.
Figure 7 SHP agonism protects against liver fibrosis development in a mice model of cholestasis. (A) Effect of ISO-COOH on AST and Alkaline phosphatase in mice administered α-naphthyl-isothiocyanate (ANIT), 10 mg/kg per os for 4 weeks. Mice were randomized after 2 weeks to receive CDCA (5 mg/kg) alone or in combination with ISO-COOH (30 mg/Kg), or ISO-COOH alone (30 mg/Kg), for two additional weeks. Data shown are: (B) Hematoxylin and eosin (H&E) staining. (C) Syrius red staining. (D) Image J quantification of Syrius red staining. Results are the mean ± SE of 6–9 mice per group. *p < 0.05, **p < 0.005, ***p < 0.0005.CC BY · PubMed Central
Figure 8 SHP activation protects against liver injury by modulating the expression of inflammatory genes. Effect of ISO-COOH on fibrosis, bile acid metabolism and inflammatory genes was assessed in mice administered α-naphthyl-isothiocyanate (ANIT), 10 mg/kg per os for 4 weeks. Mice were randomized after 2 weeks of ANIT to receive CDCA (5 mg/kg) alone or in combination with ISO-COOH (30 mg/Kg), or ISO-COOH alone (30 mg/Kg), for two additional weeks. The relative hepatic mRNA expression of αSMA, COL1α1, TGFβ1, IL1β, MCP1, NTCP, FXR, SHP, OSTα and BSEP was assayed by Real-Time PCR. Results are the mean ± SE of 6–9 mice per group. *p < 0.05, **p < 0.005, ***p < 0.0005.
Figure 8 SHP activation protects against liver injury by modulating the expression of inflammatory genes. Effect of ISO-COOH on fibrosis, bile acid metabolism and inflammatory genes was assessed in mice administered α-naphthyl-isothiocyanate (ANIT), 10 mg/kg per os for 4 weeks. Mice were randomized after 2 weeks of ANIT to receive CDCA (5 mg/kg) alone or in combination with ISO-COOH (30 mg/Kg), or ISO-COOH alone (30 mg/Kg), for two additional weeks. The relative hepatic mRNA expression of αSMA, COL1α1, TGFβ1, IL1β, MCP1, NTCP, FXR, SHP, OSTα and BSEP was assayed by Real-Time PCR. Results are the mean ± SE of 6–9 mice per group. *p < 0.05, **p < 0.005, ***p < 0.0005.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

Metadata

Authors
Cipriani, S., Carino, A., Masullo, D., Zampella, A., Distrutti, E., & Fiorucci, S.
Affiliations
  • University of Perugia (IT)
  • University of Naples Federico II (IT)
  • Azienda Ospedaliera di Perugia (IT)
Corresponding author
Fiorucci, Stefano
Venue
Scientific Reports
Published
2017-01-24
Volume
7
Issue
1
Pages
41055-41055
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2582978808
Cited by
16
References
29
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2022: 1 · 2021: 6 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 1
FWCI
0.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
small heterodimer partner, SHP, orphan nuclear receptor, hepatic stellate cells, liver fibrosis, transdifferentiation, extracellular matrix deposition, antifibrotic activity, carbon tetrachloride-induced cirrhosis, alpha-naphthylisothiocyanate, alpha-smooth muscle actin, type I collagen
MeSH terms
Animals, Carbon Tetrachloride, Disease Models, Animal, Extracellular Matrix, Gene Expression Regulation, Humans, Liver Cirrhosis, Male, 1-Naphthylisothiocyanate, Receptors, Cytoplasmic and Nuclear, Gene Expression Profiling, Mice, Rats, Hepatic Stellate Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.